This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schweizer, R. Articles by Ranke, M. B. Search for Related Content PubMed PubMed Citation Articles by Schweizer, R. Articles by Ranke, M. B. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Growth Disorders

Cortical Bone Density Is Normal in Prepubertal Children with Growth Hormone (GH) Deficiency, but Initially Decreases during GH Replacement due to Early Bone Remodeling

Pediatric Endocrinology Section, University Children’s Hospital, University of Tuebingen D-72076, Germany

Address all correspondence and requests for reprints to: Dr. Roland Schweizer, Pediatric Endocrinology Section, University Children’s Hospital, Hoppe-Seyler Strasse 1, D-72076 Tuebingen, Germany. E-mail: roland.schweizer{at}med.uni-tuebingen.de.

Dual energy x-ray absorptiometry (DEXA) has revealed that GH- deficient adults gain in bone mineral density during GH therapy. Measurements of volumetric bone density (grams per cubic centimeter vs. grams per square centimeter) and structure, however, are achieved through peripheral quantitative computed tomography (pQCT). In 45 prepubertal GH-deficient children, we studied pQCT measurements before the start and for 12 months of GH treatment. Serum alkaline phosphatase (AP), procollagen I carboxyl-terminal propeptide (PICP), and deoxypyridinoline reflected bone metabolism status. Findings at the start of GH treatment were (mean SD score): bone area, -0.44; cortical density, -0.03; cortical area, -1.32; cortical thickness, -1.41; and marrow area, +0.66. At 12 months, cortical density had fallen to -0.73 (P < 0.001), whereas cortical area and thickness, and marrow area did not change. AP, PICP, and deoxypyridinoline increased significantly within the first 3 months (increase: AP, 66.5 U/liter; PICP, 72 µg/liter; DPD, 11.4 nmol/mmol creatinine). The pQCT showed that cortical density is not reduced in GH-deficient patients. Higher bone metabolism explains the lower cortical density after GH therapy commenced. Thus, the manifestation of GH deficiency is evidently similar in children and adults, and pQCT provides important information in addition to DEXA measurements, as DEXA does not take bone structure into account.

This work was supported in part by an educational grant from Pharmacia GmbH (Erlangen, Germany) and Fortüne Forschungsförderung, a grant from University of Tuebingen.

Abbreviations: AP, Alkaline phosphatase; BMD, bone mineral density; , change in; DEXA, dual energy x-ray absorptiometry; DPD, deoxypyridinoline; GHD, GH deficiency; PICP, procollagen I carboxyl-terminal propeptide; pQCT, peripheral quantitative computed tomography; SDS, SD score.

This article has been cited by other articles:

				R. D. Murray, J. E. Adams, and S. M. Shalet A Densitometric and Morphometric Analysis of the Skeleton in Adults with Varying Degrees of Growth Hormone Deficiency J. Clin. Endocrinol. Metab., February 1, 2006; 91(2): 432 - 438. [Abstract] [Full Text] [PDF]

				G. I. Baroncelli, S. Bertelloni, L. Galli, F. Sodini, and G. Saggese Cortical Bone Density Is Normal in Prepubertal Children with Growth Hormone (GH) Deficiency, but Initially Decreases during GH Replacement due to Early Bone Remodeling J. Clin. Endocrinol. Metab., May 1, 2004; 89(5): 2505 - 2506. [Full Text] [PDF]